Alejandro Berlin

Alejandro Berlin

Auto-generated profile, based on publicly available information

Alejandro Berlin

Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2017 in Nature
Verified
Journal Article
Closed access
PDF file
MFMichael Fraser
Michael Fraser
VSVeronica Y. Sabelnykova
Veronica Y. Sabelnykova
TYTakafumi N. Yamaguchi
Takafumi N. Yamaguchi
LHLawrence E. Heisler
Lawrence E. Heisler
JLJulie Livingstone
Julie Livingstone
PBPaul C. Boutros
Paul C. Boutros

8 January 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
SCSujun Chen
Sujun Chen
GZGuanghui Zhu
Guanghui Zhu
YYYue Yang
Yue Yang
FWfubo wang
fubo wang
YXYu-Tian Xiao
Yu-Tian Xiao
SRShancheng Ren
Shancheng Ren

25 May 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PBPaul C. Boutros
Paul C. Boutros
MFMichael Fraser
Michael Fraser
NHNicholas J Harding
Nicholas J Harding
RBRichard de Borja
Richard de Borja
Dominique TrudelDominique Trudel
Dominique Trudel
RBRobert G Bristow
Robert G Bristow

1 December 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
DSDaniel Spratt
Daniel Spratt
WBWhitney H Beeler
Whitney H Beeler
FMFabio Y de Moraes
Fabio Y de Moraes
LRLaurence D Rhines
Laurence D Rhines
JGJoseph J Gemmete
Joseph J Gemmete
NSNicholas J Szerlip
Nicholas J Szerlip

1 December 2014 in The Lancet Oncology
Verified
Journal Article
Open access
ELEmilie Lalonde
Emilie Lalonde
AIAdrian S Ishkanian
Adrian S Ishkanian
JSJenna Sykes
Jenna Sykes
MFMichael Fraser
Michael Fraser
HRHelen Ross-Adams
Helen Ross-Adams
RBRobert G Bristow
Robert G Bristow
Clinical prognostic groupings for localised prostate cancers are imprecise, with 30-50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We aimed to test combined genomic and microenvironmental indices in prostate cancer to improve risk stratification and complement clinical prognostic factors. We used DNA-based indices alone or in combination with intra-prostatic hypoxia measurements to develop four prognostic indices in 126 low-risk to intermediate-risk patients (Toronto cohort) who will receive image-guided radiotherapy. We validated these indices in two independent cohorts of 154 (Memorial Sloan Kettering Cancer Center cohort [MSKCC] cohort) and 117 (Cambridge cohort) radical prostatectomy specimens from low-risk to high-risk patients. We applied unsupervised and supervised machine learning techniques to the copy-number profiles of 126 pre-image-guided radiotherapy diagnostic biopsies to develop prognostic signatures. Our primary endpoint was the development of a set of prognostic measures capable of stratifying patients for risk of biochemical relapse 5 years after primary treatment. Biochemical relapse was associated with indices of tumour hypoxia, genomic instability, and genomic subtypes based on multivariate analyses. We identified four genomic subtypes for prostate cancer, which had different 5-year biochemical relapse-free survival. Genomic instability is prognostic for relapse in both image-guided radiotherapy (multivariate analysis hazard ratio [HR] 4·5 [95% CI 2·1-9·8]; p=0·00013; area under the receiver operator curve [AUC] 0·70 [95% CI 0·65-0·76]) and radical prostatectomy (4·0 [1·6-9·7]; p=0·0024; AUC 0·57 [0·52-0·61]) patients with prostate cancer, and its effect is magnified by intratumoral hypoxia (3·8 [1·2-12]; p=0·019; AUC 0·67 [0·61-0·73]). A novel 100-loci DNA signature accurately classified treatment outcome in the MSKCC low-risk to intermediate-risk cohort (multivariate analysis HR 6·1 [95% CI 2·0-19]; p=0·0015; AUC 0·74 [95% CI 0·65-0·83]). In the independent MSKCC and Cambridge cohorts, this signature identified low-risk to high-risk patients who were most likely to fail treatment within 18 months (combined cohorts multivariate analysis HR 2·9 [95% CI 1·4-6·0]; p=0·0039; AUC 0·68 [95% CI 0·63-0·73]), and was better at predicting biochemical relapse than 23 previously published RNA signatures. This is the first study of cancer outcome to integrate DNA-based and microenvironment-based failure indices to predict patient outcome. Patients exhibiting these aggressive features after biopsy should be entered into treatment intensification trials. Movember Foundation, Prostate Cancer Canada, Ontario Institute for Cancer Research, Canadian Institute for Health Research, NIHR Cambridge Biomedical Research Centre, The University of Cambridge, Cancer Research UK, Cambridge Cancer Charity, Prostate Cancer UK, Hutchison Whampoa Limited, Terry Fox Research Institute, Princess Margaret Cancer Centre Foundation, PMH-Radiation Medicine Program Academic Enrichment Fund, Motorcycle Ride for Dad (Durham), Canadian Cancer Society.

10 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
MDMatthew P. Deek
Matthew P. Deek
KEKim Van der Eecken
Kim Van der Eecken
PSPhilip Anthony Sutera
Philip Anthony Sutera
RDRebecca A. Deek
Rebecca A. Deek
VFValérie Fonteyne
Valérie Fonteyne
PTPhuoc Tran
Phuoc Tran
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1/ 2, Rb1, or TP53. The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.